This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Heller, L. Articles by Heller, R. Search for Related Content PubMed PubMed Citation Articles by Heller, L. Articles by Heller, R.

Evaluation of Toxicity following Electrically Mediated Interleukin-12 Gene Delivery in a B16 Mouse Melanoma Model

Authors' Affiliations: ¹ Department of Medical Microbiology and Immunology and ² Center for Molecular Delivery, University of South Florida; ³ Department of Interdisciplinary Oncology and ⁴ Cutaneous Oncology Program, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida

Requests for reprints: Richard Heller, Department of Medical Microbiology and Immunology, University of South Florida College of Medicine, MDC Box 16, 12901 Bruce B. Downs Boulevard, Tampa, FL 33612. Phone: 813-974-3065; Fax: 813-974-3339; E-mail: rheller{at}hsc.usf.edu.

Purpose: Interleukin-12 (IL-12) has potential as an immunotherapeutic agent for the treatment of cancer but is unfortunately associated with toxicity. Delivery of a plasmid encoding IL-12 with electroporation induces an antitumor effect in the B16 mouse melanoma model without serious side effects. To translate this observation to the clinic, an evaluation of toxicity was done in the mouse model.

Experimental Design: Weight change, tumor response, blood chemistry and hematology values, and serum IL-12 levels were evaluated. Multiple tissues were analyzed histopathologically.

Results: A pronounced reduction in tumor volume, including a large percentage of complete regressions, was observed after electrically mediated gene therapy. No significant increases in serum IL-12 levels were detected. Tumor-bearing mice showed an increased number of atypical hematology values when compared with normal naive controls. Statistically significant differences in chemistry and hematology values were observed sporadically in most of the standard chemistry and hematology categories in all groups. The only histopathologic abnormality specific to the animals receiving both plasmid and electroporation was inflammation associated with the kidney at the last time point.

Conclusions: In general, mice that received both plasmid and electroporation showed the least abnormal histopathologic findings and were found to be in the best health, reflecting the reduced burden of disease. No significant toxic effects due to the IL-12 gene therapy were observed.

This article has been cited by other articles:

				A. I. Daud, R. C. DeConti, S. Andrews, P. Urbas, A. I. Riker, V. K. Sondak, P. N. Munster, D. M. Sullivan, K. E. Ugen, J. L. Messina, et al. Phase I Trial of Interleukin-12 Plasmid Electroporation in Patients With Metastatic Melanoma J. Clin. Oncol., December 20, 2008; 26(36): 5896 - 5903. [Abstract] [Full Text] [PDF]